Retrospective cohort study evaluating exenatide twice daily and long-acting @entity2690 analogs in a Veterans Health Administration population with type 2 XXXX .

@entity1 @entity2690 @entity6 @entity4051
AIM: This was a retrospective cohort study that evaluated the differences in glycated haemoglobin (HbA1c) and body mass index (BMI) in veterans with @entity6 ( @entity6 ), prescribed exenatide twice daily (BID) versus long-acting @entity2690 analog (LAIA) two years after initiation in the United States (US) veteran population. MATERIALS AND METHODS: @entity1 were included if they were >=  18 years old with @entity6 , and initiated exenatide BID or LAIA at the Veterans Health Administration between January 1, 2006 and December 31, 2010. Multivariate models were used to evaluate the changes in HbA1c and BMI between groups, controlling for potential confounders. Logistic regression was used to evaluate the odds of achieving >=  0.5% @entity4051 c reduction based on baseline @entity4051 c stratifications: low,<7%; moderate, 7% to<9%; and high,>=  9%. RESULTS: A total of 446 exenatide BID and 51,531 LAIA @entity1 met inclusion/exclusion criteria. On average, exenatide BID @entity1 were significantly older (64 versus 60 years) with a higher BMI (37.8 versus 32.9 kg/m(2)). Baseline HbA1c was 8.2% and 8.8% for exenatide BID and LAIA @entity1 , respectively (P<0.001); otherwise, @entity1 were similar for all other characteristics. Exenatide BID treatment was significantly associated with a 0.32% (95%CI: 0.18-0.47%) greater reduction in HbA1c at two years compared with LAIA. Similar findings were observed for BMI reduction (0.68 kg/m(2); 95%CI: 0.42-0.95 kg/m(2)). Exenatide BID @entity1 with moderate baseline @entity4051 c had significantly higher odds of achieving >=  0.5% HbA1c reduction compared with LAIA @entity1 (OR=1.5; 95%CI: 1.2-2.0). CONCLUSIONS: Veterans treated with exenatide BID had significantly greater reduction in HbA1c and BMI compared with @entity1 treated with LAIA @entity1 two years after initiation.
